Gaspari A A, Cheng S F, DiPersio J F, Rowe J M
Department of Dermatology, University of Rochester School of Medicine and Dentistry, NY, USA.
J Am Acad Dermatol. 1995 Nov;33(5 Pt 1):711-7. doi: 10.1016/0190-9622(95)91806-x.
Roquinimex is being used for posttransplantation immunotherapy of autologous bone marrow transplantation for acute and chronic myelogenous leukemia. This immunotherapeutic agent is a cytokine inducer and may induce an autologous graft-versus-host (GVH) and graft-versus-tumor reactions.
Our purpose was to examine patients undergoing this immunotherapy for clinical signs and symptoms of acute GVH reactions and to correlate these symptoms with their clinical outcome.
We studied eight patients receiving requinimex therapy.
We found autologous GVH reactions in three of eight patients (38%) treated with this immunotherapy. Their disease was manifested by localized or widespread violaceous papules that on histologic evaluation were compatible with a grade II GVH reaction. The acute cutaneous GVH reaction was associated with eccrine sweat gland necrosis, a dermatologic toxicity usually associated with chemotherapy.
Long-term studies of larger numbers of patients treated with this immunotherapy will determine whether these GVH reactions confer significant, sustained, antitumor effects.
罗喹美克正用于急性和慢性粒细胞白血病自体骨髓移植的移植后免疫治疗。这种免疫治疗药物是一种细胞因子诱导剂，可能诱发自体移植物抗宿主（GVH）反应和移植物抗肿瘤反应。
我们的目的是检查接受这种免疫治疗的患者是否出现急性GVH反应的临床体征和症状，并将这些症状与其临床结局相关联。
我们研究了8例接受罗喹美克治疗的患者。
我们发现接受这种免疫治疗的8例患者中有3例（38%）出现了自体GVH反应。他们的疾病表现为局部或广泛的紫红色丘疹，组织学评估显示与II级GVH反应相符。急性皮肤GVH反应与小汗腺坏死有关，小汗腺坏死是一种通常与化疗相关的皮肤毒性。
对大量接受这种免疫治疗的患者进行长期研究将确定这些GVH反应是否能带来显著、持续的抗肿瘤效果。
